Tecan Group has announced the acquisition of ELISA immunoassay products from Cisbio Bioassays to enhance its specialty diagnostics portfolio.

Information on the Target

Tecan Group (SIX Swiss Exchange: TECN), based in Männedorf, Switzerland, has announced plans to acquire specific assets related to key ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of Revvity Inc. This acquisition includes the manufacturing processes for four ELISA kits: two in vitro diagnostic (IVD) products designed for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits. This acquisition marks a significant enhancement to Tecan's offerings in the rapidly evolving landscape of specialty diagnostics.

Industry Overview in Switzerland

Switzerland boasts a robust life sciences industry, renowned for its innovation and high standards in both diagnostics and therapeutic development. The country's regulatory framework ensures that products meet stringent safety and efficacy standards, which is crucial for maintaining public trust and facilitating market access. The presence of major global players, alongside a supportive ecosystem for startups, makes Switzerland a leading hub for life sciences.

In recent years, the Swiss market has demonstrated strong growth, particularly in the realm of diagnostics. The continuous expansion of research activities, alongside increasing healthcare expenditures, is fostering an environment w